NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
Status:
Unknown status
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
NP202 is an experimental drug being developed by Armaron Bio Pty Ltd for potential use as a
treatment for people after they have had a heart attack (MI).